← Leaderboards
Christian Maximillian Schmidt
Indiana Univ-Purdue Univ At Indianapolis
$2,390,358
Attributed
$4,210,223
Total exposure
4
Grants
3
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $677.8K · FY2006–25$1M$750K$500K$250K$0
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$4,210,223 · 4
By mechanism
U01$3,264,543 · 1
R21$796,377 · 2
R03$149,303 · 1
Top collaborators
- Jianjun Zhang7 shared
Others in their field
Top investigators on “Public Health Relevance”
- James Dennis Neaton · Northwestern University$207,438,295
- Sharon A Nachman · Johns Hopkins University$197,601,947
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$187,622,842
- Jeffrey P Krischer · University Of South Florida$163,793,528
- George R Seage · Abt Associates, Inc.$128,298,055
- Harry P Selker · Virginia Commonwealth University$123,247,735
Research focus
Public Health RelevanceMalignant NeoplasmsIncidenceMalignant Neoplasm Of PancreasMalignant - DescriptorMucinous NeoplasmPapillaryBiological MarkersMortalityCystPlasmaCohortHigh RiskMetabolomicsPathologyOperative Surgical ProceduresExcisionPancreatic CystGuidelinesCa-19-9 AntigenClinical/RadiologicBenignIndianaPhysicians
Grant awards (11)
Longitudinal Proteomic and Metabolomic Predictors of Pancreatic Cyst Malignant Progression and Early Stage Pancreatic Cancer$661,420
U01 · FY2025 · CA · contact PI
Longitudinal Proteomic and Metabolomic Predictors of Pancreatic Cyst Malignant Progression and Early Stage Pancreatic Cancer$628,354
U01 · FY2024 · CA · contact PI
Longitudinal Proteomic and Metabolomic Predictors of Pancreatic Cyst Malignant Progression and Early Stage Pancreatic Cancer$648,229
U01 · FY2023 · CA · contact PI
Longitudinal Proteomic and Metabolomic Predictors of Pancreatic Cyst Malignant Progression and Early Stage Pancreatic Cancer$648,753
U01 · FY2022 · CA · contact PI
Longitudinal Proteomic and Metabolomic Predictors of Pancreatic Cyst Malignant Progression and Early Stage Pancreatic Cancer$677,787
U01 · FY2021 · CA · contact PI
Identifying insulin resistance biomarkers and metabolomic signature as predictors of precursors to pancreatic cancer$171,281
R21 · FY2017 · CA
Identifying insulin resistance biomarkers and metabolomic signature as predictors of precursors to pancreatic cancer$203,906
R21 · FY2016 · CA
Mechanism of Alcohol/Alcoholism-induced Liver Neoplasia$228,690
R21 · FY2010 · AA · contact PI
Mechanism of Alcohol/Alcoholism-induced Liver Neoplasia$192,500
R21 · FY2009 · AA · contact PI
Biomarkers of COX-2 inhibitors in intraductal papillary mucinous neoplasm (IPMN)$73,553
R03 · FY2007 · CA · contact PI
A Biomarker Study of COX-2 Inhibitors in IPMN$75,750
R03 · FY2006 · CA · contact PI